Initial outcomes of a dedicated multidisciplinary non-alcoholic fatty liver disease clinic: a retrospective cohort study.

Autor: Commins I; Department of Gastroenterology, Alfred Health, Melbourne, Australia., Clayton-Chubb D; Department of Gastroenterology, Alfred Health, Melbourne, Australia.; Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia., Melton S; Department of Nutrition and Dietetics, Alfred Health, Melbourne, Australia., Majeed A; Department of Gastroenterology, Alfred Health, Melbourne, Australia.; Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia., Kemp W; Department of Gastroenterology, Alfred Health, Melbourne, Australia.; Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia., Roberts SK; Department of Gastroenterology, Alfred Health, Melbourne, Australia.; Department of Medicine, Central Clinical School, Monash University, Melbourne, Australia.
Jazyk: angličtina
Zdroj: Internal medicine journal [Intern Med J] 2023 Nov; Vol. 53 (11), pp. 2065-2072. Date of Electronic Publication: 2023 Apr 18.
DOI: 10.1111/imj.16055
Abstrakt: Background: Non-alcoholic fatty liver disease (NAFLD) is a major healthcare burden. Real-world outcomes in dedicated tertiary care settings in Australia remain unknown.
Aim: To evaluate the initial outcomes of patients referred to a dedicated multidisciplinary tertiary care NAFLD clinic.
Methods: Retrospective review of all adult patients with NAFLD who attended a dedicated tertiary care NAFLD clinic between January 2018 and February 2020 and who had two clinic visits and FibroScans at least 12 months apart. Demographic and health-related clinical and laboratory data were extracted from electronic medical records. Key outcome measures were serum liver chemistries, liver stiffness measurement (LSM) and weight control at 12 months.
Results: A total of 137 patients with NAFLD were included. Median (interquartile range (IQR)) follow-up time was 392 days (343-497 days). One hundred and eleven patients (81%) achieved weight control (i.e. weight loss or stability). Markers of liver disease activity were significantly improved, including median (IQR) serum alanine aminotransferase (48 (33-76) vs 41 (26-60) U/L, P = 0.009) and aspartate aminotransferase (35 (26-54) vs 32 (25-53) U/L, P = 0.020). Median (IQR) LSM across the whole cohort was significantly improved (8.4 (5.3-11.8) vs 7.0 (4.9-10.1) kPa, P = 0.001). No significant reduction was observed in mean body weight or the frequency of metabolic risk factors.
Conclusions: This study highlights a new model of care for patients with NAFLD and demonstrates promising initial outcomes in relation to significant reductions in markers of liver disease severity. Although most patients achieved weight control, further refinements are needed to achieve significant weight reduction including more frequent and structured dietetic and/or pharmacotherapeutic interventions.
(© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.)
Databáze: MEDLINE
Externí odkaz: